Intratumoral Cancer Treatment Market Size, Epidemiology, Drugs Pipeline, Market Analysis And Companies By DelveInsight

October 27 02:36 2021
Intratumoral Cancer Treatment Market Size, Epidemiology, Drugs Pipeline, Market Analysis And Companies By DelveInsight
Intratumoral Cancer Treatment Market

DelveInsight’s Intratumoral Cancer Therapies Market report offers detailed information on current treatment practices, emerging drugs, Intratumoral Cancer Therapies market share of the individual therapies, current and forecasted Intratumoral Cancer Therapies market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Some facts of Intratumoral Cancer Therapies Market Report:

  • Out of all the major cancers studied, i.e., Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma, Nonmelanoma skin cancer (NMSC) contributed to the highest number of cases in the 7MM.
  • As per DelveInsight’s estimates, the total NMSC incident cases in the 7MM was 774,926 in 2020.
  • At present, there are only three Intratumoral approved drugs namely Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Hensify (NBTXR3; Nanobiotix) and Delytact (teserpaturev/G47∆; Daiichi Sankyo). Imlygic (Amgen) is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors.
  • The highest Intratumoral Cancer Therapies market share is primarily dominated by the USA in the 7MM that is anticipated to soar at a CAGR of 43% by 2030.
  • The majority of the emerging therapies are working on the principle of turning “cold” tumors to “hot” and then simultaneously targeting the tumor with immune checkpoint inhibitors.

 

Download Intratumoral Cancer Therapies Market Snapshot report to understand which Intratumoral Cancer Therapy is going to nab the maximum market share @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market

 

Intratumoral Cancer Therapies: Disease Overview

The cancer treatment landscape has transformed to incorporate novel therapies which mainly include chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there are patients who do not respond to any of the available treatment options or develop resistance to available therapies.

Recently, the scientific community has developed a keen interest in Intratumoral Cancer Therapies that are immunotherapies administered directly into tumors via injections, however, they can refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors.

 

Intratumoral Cancer Therapies: Indication-wise Segmentation

DelveInsight’s Intratumoral Cancer Therapies Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

  • Total Incident Cases of Selected Cancer Types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)
  • Target Patient Pool of Intratumoral Therapies by Cancer Types
  • Treated Cases by Cancer Types

 

Understand how Intratumoral Cancer Therapeutics Landscape is going to shape by 2030 in 7 Major Markets by downloading @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market

 

Intratumoral Cancer Pipeline Therapies in Focus in the Report Analysis

Currently, the Intratumoral Cancer Therapy pipeline is rich with potential candidates majorly focused on the treatment of melanoma, head and neck cancer, Nonmelanoma skin cancer, along with some other cancers and expectations are high from Intratumoral Cancer Therapies.

Most of the emerging therapies are simultaneously targeting the tumor in tandem with immune checkpoint inhibitors. DelveInsight’s analysts estimate that out of all cancer types assessed, Melanoma is anticipated to dominate the Intratumoral Cancer Therapeutic market landscape.

  • Vidutolimod (CMP-001): Checkmate Pharmaceuticals
  • TAVO(tavokinogene telseplasmid): OncoSec Medical Incorporated
  • CAVATAK (V937; CVA21): Merck & Co (Viralytics)
  • PVSRIPO (PVS-RIPO): Istari Oncology
  • RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
  • Daromun (Nidlegy): Philogen
  • Cavrotolimod (AST-008): Exicure
  • Cotsiranib (STP705): Sirnaomics
  • Hensify (NBTXR3/ PEP503): Nanobiotix
  • INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
  • NanoPac (LSAM paclitaxel): NanOlogy
  • Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
  • Intuvax (Ilixadencel): Immunicum
  • Tasadenoturev (DNX-2401): DNAtrix
  • G207: Treovir
  • Tilsotolimod (IMO-2125): Idera Pharmaceuticals
  • AlloStim: Immunovative Therapies

 

Learn more about available treatments @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market 

 

Intratumoral Cancer Therapies Market Dynamics

DelveInsight’s Intratumoral Cancer Therapies market analysis demonstrates that these therapies have immense potential to transform the treatment landscape by turning cold tumors into hot tumor and making their identification convenient by the immune system.  However, the present understanding of Intratumoral therapies is poor and they also have faced backlash from the recent clinical trial failures at late stages; DelveInsight estimates that the future carries a promising outlook for the Intratumor Cancer Therapies market owing to potential emerging therapies, promising clinical trial results, the influx of pharma and biotech players, better R&D, and increasing healthcare expenditure.

 

Table of Contents 

1 Key Insights
2  Executive Summary of Intratumoral Cancer Therapies
3 Intratumoral Cancer Therapies Market Overview at a Glance
4 Competitive Intelligence Analysis for Intratumoral Cancer Therapies
5 Intratumoral Cancer Therapies Disease Background and Overview
6 Algorithm for Diagnosis of Intratumoral Cancer Therapies
7 Intratumoral Cancer Therapies Patient Journey
8 Intratumoral Cancer Therapies Epidemiology and Patient Population
9 Treatment Algorithm, Current Treatment, and Medical Practices
10 Intratumoral Cancer Therapies Epidemiology and Patient Population
11 Country Wise Epidemiology of Intratumoral Cancer Therapies
10 Intratumoral Cancer Therapies Treatment
12 Access and Reimbursement Overview of Intratumoral Cancer Therapies
13 Key Endpoints of Intratumoral Cancer Therapies Treatment
14 Intratumoral Cancer Therapies Emerging Therapies
15 Intratumoral Cancer Therapies: 7 Major Market Analysis
16 Intratumoral Cancer Therapies Market Unmet Needs
17 Intratumoral Cancer Therapies Market Drivers
18 Intratumoral Cancer Therapies Market Barriers
19 Attribute Analysis
20 KOL Reviews
21 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market